Keros Therapeutics, Inc. $KROS Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC lifted its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 1,420.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 98,703 shares of the company’s stock after purchasing an additional 92,212 shares during the period. SG Americas Securities LLC owned about 0.32% of Keros Therapeutics worth $2,010,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Western Standard LLC boosted its holdings in Keros Therapeutics by 42.7% in the 3rd quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock worth $34,644,000 after buying an additional 654,989 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of Keros Therapeutics during the second quarter valued at approximately $4,251,000. Caption Management LLC lifted its position in shares of Keros Therapeutics by 114.1% in the second quarter. Caption Management LLC now owns 36,078 shares of the company’s stock valued at $482,000 after acquiring an additional 291,997 shares in the last quarter. Qube Research & Technologies Ltd lifted its position in shares of Keros Therapeutics by 683.7% in the third quarter. Qube Research & Technologies Ltd now owns 303,122 shares of the company’s stock valued at $4,795,000 after acquiring an additional 264,445 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Keros Therapeutics by 38.3% in the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock worth $7,547,000 after acquiring an additional 205,022 shares during the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Price Performance

Shares of NASDAQ:KROS opened at $12.00 on Monday. Keros Therapeutics, Inc. has a 52-week low of $9.12 and a 52-week high of $22.55. The stock has a market cap of $236.64 million, a P/E ratio of 6.59 and a beta of 0.98. The business has a fifty day moving average of $14.23 and a two-hundred day moving average of $16.47.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, March 4th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.37). Keros Therapeutics had a return on equity of 14.25% and a net margin of 35.65%.The company had revenue of $0.39 million for the quarter, compared to analysts’ expectations of $3.66 million. During the same quarter in the prior year, the firm earned ($1.14) EPS. The firm’s revenue was down 87.2% on a year-over-year basis. On average, equities analysts anticipate that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on KROS. Wall Street Zen downgraded Keros Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. TD Cowen raised shares of Keros Therapeutics to a “hold” rating in a research note on Friday, December 19th. Zacks Research cut shares of Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Weiss Ratings reissued a “sell (d+)” rating on shares of Keros Therapeutics in a research note on Monday, December 29th. Finally, Wells Fargo & Company lowered their price target on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, March 5th. Five research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $21.86.

Keros Therapeutics Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.